April 29th 2024
Tisotumab vedotin-tftv may now be given to patients with recurrent or metastatic cervical cancer, according to the FDA.
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Questions We Should Be Asking About Bevacizumab for Cervical Cancer
May 15th 2015There is good evidence that angiogenesis plays a central role in cervical cancer pathogenesis, suggesting a strong rationale for adding anti-angiogenesis agents to chemotherapeutic agents for the treatment of this disease.
ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality
June 7th 2013Biennial visual inspection with acetic acid (vinegar) screening by trained public health workers significantly reduced cervical cancer mortality in a large cluster-randomized controlled trial conducted among thousands of women from poor neighborhoods in Mumbai, India.
Study: US Cancer Screening Rates Declined Over Last Decade
January 4th 2013There has been a decline in overall cancer screening among the US population. Only colorectal cancer screening rates met current screening goals. Cancer survivors specifically met current national screening goals with the exception of cervical cancer screening.